The principle investigator Dr. Devalingam Mahalingam, M.D., PhD., of the GI/thoracic oncology and drug development at the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has revealed that the primary endpoint for a first stage Phase 2 Metastatic Melanoma Trial involving Oncolytics Biotech’s REOLYSIN in combination with carboplatin and paclitaxel (REO 020) has been completed.
http://bionews-tx.com/news/2013/05/23/ut-health-science-center-researcher-leads-successful-phase-2-trial-of-oncolytics-biotechs-reolysin/
No comments:
Post a Comment